Concurrent loss of Lkb1 and Tp53 inactivation promotes the development of osteosarcoma, lymphoma, sarcoma (Wei et al., 2005) and hepatic carcinoma in vivo (Takeda et al., 2006). This evidence concerns the gene STK11 and hepatocellular carcinoma.